HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Is tissue inhibitor of metalloproteinase-1 a new prognosticator for breast cancer? An analysis of 266 cases.

Abstract
Overexpression of tissue inhibitor of metalloproteinase-1 at either the messenger RNA or protein level has been related to a poorer prognosis in breast cancer. We investigated the role of tissue inhibitor of metalloproteinase-1 tissue expression, which was evaluated by immunohistochemistry staining of paraffin-embedded samples, as a possible prognostic indicator in breast cancer. The study included 266 patients treated by primary surgery. Tumors were scored tissue inhibitor of metalloproteinase-1 positive when at least 10% of the cells showed moderate or strong staining. Staining was observed in 76 (28.6%) patients; by multivariate analysis, factors independently associated with tissue inhibitor of metalloproteinase-1 positivity included more than 9 metastatic axillary nodes, high Mib-1 expression, and positivity for plasminogen activator inhibitor and CD44. With a median follow-up of 125 months, tissue inhibitor of metalloproteinase-1 expression showed a significant prognostic role in disease-free and overall survival by univariate analysis. Multivariate analysis confirmed an independent negative prognostic impact of tissue inhibitor of metalloproteinase-1 on overall but not disease-free together with high values of Mib-1. The number of involved axillary nodes, and triple negativity were independent predictors of either poorer disease-free or overall survival. In our study, tissue inhibitor of metalloproteinase-1 expression was significantly related to markers of tumor aggressiveness and was a powerful indicator of poorer prognosis, with a difference in 10-year disease-free and overall survival of 14% and 28%, respectively, between tissue inhibitor of metalloproteinase-1-negative and tissue inhibitor of metalloproteinase-1-positive cases. Expression of tissue inhibitor of metalloproteinase-1 also was an independent prognostic factor in node-positive cases, indicating a possible role of tissue inhibitor of metalloproteinase-1 as a marker of reduced chemosensitivity. Thus, tissue inhibitor of metalloproteinase-1 may have a role in clinical practice as a prognostic and predictive factor and a possible target for future therapies.
AuthorsAlessandro Neri, Tiziana Megha, Francesca Bettarini, Damiana Tacchini, Maria Grazia Mastrogiulio, Daniele Marrelli, Enrico Pinto, Piero Tosi
JournalHuman pathology (Hum Pathol) Vol. 43 Issue 8 Pg. 1184-91 (Aug 2012) ISSN: 1532-8392 [Electronic] United States
PMID22397869 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 Elsevier Inc. All rights reserved.
Chemical References
  • Biomarkers, Tumor
  • Hyaluronan Receptors
  • Plasminogen Activator Inhibitor 1
  • Tissue Inhibitor of Metalloproteinase-1
Topics
  • Adenocarcinoma, Mucinous (metabolism, pathology)
  • Adult
  • Aged
  • Aged, 80 and over
  • Axilla (pathology)
  • Biomarkers, Tumor (metabolism)
  • Breast (metabolism)
  • Breast Neoplasms (metabolism, pathology)
  • Carcinoma, Ductal, Breast (metabolism, pathology)
  • Carcinoma, Lobular (metabolism, pathology)
  • Female
  • Humans
  • Hyaluronan Receptors (metabolism)
  • Middle Aged
  • Plasminogen Activator Inhibitor 1 (metabolism)
  • Prognosis
  • Retrospective Studies
  • Tissue Inhibitor of Metalloproteinase-1 (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: